GALERA THERAPEUTICS, INC. (GRTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
GRTX Stock Price Chart Interactive Chart >
GRTX Price/Volume Stats
| Current price | $2.45 | 52-week high | $2.85 |
| Prev. close | $2.44 | 52-week low | $1.12 |
| Day low | $2.40 | Volume | 210,904 |
| Day high | $2.64 | Avg. volume | 154,160 |
| 50-day MA | $1.77 | Dividend yield | N/A |
| 200-day MA | $1.59 | Market Cap | 69.83M |
GALERA THERAPEUTICS, INC. (GRTX) Company Bio
Galera Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on the prevention of radiation-induced toxicity, including mucositis and the treatment of fibrosis and cancer. The company was founded by Robert A. Beardsley, Randy W. Weiss, and Dennis P. Riley in 2009 and is headquartered in Malvern, PA.
Latest GRTX News From Around the Web
Below are the latest news stories about GALERA THERAPEUTICS INC that investors may wish to consider to help them evaluate GRTX as an investment opportunity.
Malvern-based Galera shares rise on FDA filing for lead cancer therapy drugShares of Chester County biopharmaceutical company developing new cancer therapies opened up 9% Monday after filing its first new drug application with the Food and Drug Administration. Galera Therapeutics (NASDAQ: GRTX) of Malvern is seeking approval for avasopasem as a treatment for radiotherapy-induced severe oral mucositis in patients with head and neck cancer. There are no FDA-approved treatment for severe oral mucositis. |
Galera Submits New Drug Application for Avasopasem for Severe Oral MucositisNDA based on two positive randomized, double-blinded, placebo-controlled trials which enrolled a total of 678 patientsMALVERN, Pa., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administr |
Galera to Present at Piper Sandler Annual Healthcare ConferenceMALVERN, Pa., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29, 2022 at 11:10 a.m. E.T. A live webcast of the |
Galera Reports Third Quarter 2022 Financial Results and Recent Corporate UpdatesCompany on track to submit NDA to U.S. FDA for avasopasem by end of 2022 One-year ROMAN follow-up data presented at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting showed tumor outcomes and overall survival maintained compared to placebo One-year ROMAN follow-up data also showed cisplatin-related chronic kidney disease reduced by 50% in avasopasem patients compared to placebo Meta-analysis of both randomized placebo-controlled trials of avasopasem (ROMAN and GT-201) further u |
One Galera Therapeutics, Inc. (NASDAQ:GRTX) insider upped their stake by 50% in the previous yearViewing insider transactions for Galera Therapeutics, Inc.'s ( NASDAQ:GRTX ) over the last year, we see that insiders... |
GRTX Price Returns
| 1-mo | 64.43% |
| 3-mo | 67.81% |
| 6-mo | 102.48% |
| 1-year | -10.58% |
| 3-year | -83.49% |
| 5-year | N/A |
| YTD | 64.43% |
| 2022 | -67.54% |
| 2021 | -55.13% |
| 2020 | -22.26% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...